Extent of Beta 1- and Beta 2-receptor Occupancy in Plasma Assesses the Antagonist Activity of Metoprolol, Pindolol, and Propranolol in the Elderly

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 1993 Dec 1

PMID 7912102

Authors

T Kaila

E IISALO

A Lehtonen

H Saarimaa

Affiliations

Soon will be listed here.

Abstract

We estimated antagonist activity of metoprolol, pindolol, and propranolol in elderly cardiovascular patients by determining the extent to which the drugs occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples during drug treatment. The randomized, double-blind, crossover study was carried out by administering twice daily 100 mg metoprolol, 5 mg pindolol, and 80 mg propranolol for 7 days to 20 hypertensive subjects with a mean age of about 70 years. A 2-week interval was kept between administration of the different regimens. Receptor occupancy was measured at 1 hour before and 2 hours after administration of the last dose of each regimen by adding rabbit lung beta 1- and rat reticulocyte beta 2-receptors to plasma samples and by labeling the receptors with a radiolabeled beta-antagonist, (-)-[3H]CGP-12177. The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade. (b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments. The mean beta 1-receptor occupancy of the metoprolol regimen varied between 54% and 92%, and its beta 2-receptor occupancy varied between 6% and 38%. Thus the antagonist activity of the metoprolol regimen differed significantly from that of the other regimens (ANOVA for repeated measures, p < 0.05 and 0.001, for the beta 1- and beta 2-occupancy, respectively). (c) The extent of beta 1- and beta 2-receptor occupancy in plasma samples was in conformity with the literature on the intensity, selectivity, and duration of beta-blockade after similar drug doses. (d) The data on the receptor occupancy of beta-blocking drugs in plasma samples appear to be valuable in analyzing their effects, and it may be a method for optimizing drug therapy for aged cardiovascular patients.

References

Koch-Weser J . Drug therapy: metoprolol. N Engl J Med. 1979; 301(13):698-703. DOI: 10.1056/NEJM197909273011306. View

Wellstein A, Palm D, Belz G, Pitschner H . Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers. Arzneimittelforschung. 1985; 35(1):2-6. View

Kendall M, Akhlaghi S, Hughes B, Lewis H . Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol?. J Clin Pharmacol. 1990; 30(S2):S98-102. DOI: 10.1002/j.1552-4604.1990.tb03505.x. View

Kaila T, IISALO E . Selectivity of acebutolol, atenolol, and metoprolol in healthy volunteers estimated by the extent the drugs occupy beta 2-receptors in the circulating plasma. J Clin Pharmacol. 1993; 33(10):959-66. DOI: 10.1002/j.1552-4604.1993.tb01930.x. View

Juberg E, Minneman K, Abel P . Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985; 330(3):193-202. DOI: 10.1007/BF00572434. View

Walle U, Walle T, Bai S, Olanoff L . Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther. 1983; 34(6):718-23. DOI: 10.1038/clpt.1983.240. View

Wellstein A, Palm D, Wiemer G, Schafer-Korting M, Mutschler E . Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma. Eur J Clin Pharmacol. 1984; 27(5):545-53. DOI: 10.1007/BF00556890. View

Hawksworth G, Betts T, Crowe A, Knight R, Parry K, Petrie J . Diazepam/beta-adrenoceptor antagonist interactions. Br J Clin Pharmacol. 1984; 17 Suppl 1:69S-76S. PMC: 1463275. DOI: 10.1111/j.1365-2125.1984.tb02431.x. View

Brown E, FEDAK S, Woodard C, Aurbach G . Beta-Adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity. J Biol Chem. 1976; 251(5):1239-46. View

10.

McPherson G . Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods. 1985; 14(3):213-28. DOI: 10.1016/0160-5402(85)90034-8. View

11.

Fitzgerald J, ODonnell S . Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol. 1971; 43(1):222-35. PMC: 1665931. DOI: 10.1111/j.1476-5381.1971.tb07171.x. View

12.

ODonnell S, Wanstall J . Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues. Life Sci. 1980; 27(8):671-7. DOI: 10.1016/0024-3205(80)90008-9. View

13.

McDevitt D . In vivo studies on the function of cardiac beta-adrenoceptors in man. Eur Heart J. 1989; 10 Suppl B:22-8. DOI: 10.1093/eurheartj/10.suppl_b.22. View

14.

Gretzer I, Alvan G, DUNER H, Garle M, Sjoqvist F . Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients. Eur J Clin Pharmacol. 1986; 31(4):415-8. DOI: 10.1007/BF00613516. View

15.

Benfield P, Clissold S, Brogden R . Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs. 1986; 31(5):376-429. DOI: 10.2165/00003495-198631050-00002. View

16.

von Bahr C, Hermansson J, Tawara K . Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man. Br J Clin Pharmacol. 1982; 14(1):79-82. PMC: 1427572. DOI: 10.1111/j.1365-2125.1982.tb04937.x. View

17.

Brodde O, Kuhlhoff F, Arroyo J, Prywarra A . No evidence for temperature-dependent changes in the pharmacological specificity of beta 1- and beta 2-adrenoceptors in rabbit lung membranes. Naunyn Schmiedebergs Arch Pharmacol. 1983; 322(1):20-8. DOI: 10.1007/BF00649347. View

18.

Wellstein A, Palm D, Pitschner H, Belz G . Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol. 1985; 29(2):131-47. DOI: 10.1007/BF00547412. View

19.

STAEHELIN M, Simons P, Jaeggi K, Wigger N . CGP-12177. A hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem. 1983; 258(6):3496-502. View

20.

George C . The rationale of treating high blood pressure in the elderly. Age Ageing. 1979; 8(2):110-4. DOI: 10.1093/ageing/8.2.110. View